Vaxess provides a platform that combines a proprietary microarray patch and applicator capable of delivering diverse therapeutic payloads. Its dissolvable microarray tips are made from advanced biomaterials that enable precise dose-delivery control and can be modified for different payloads. The patch does not require refrigeration, which the company says enables delivery to low-resource settings. Vaxess intends to use the new funding to advance its work on GLP-1 and to expand manufacturing capabilities to support its lead program. The company also plans to support new partnerships for additional therapeutics. The company is led by CEO Rachel Sha and is based in Woburn, MA. Vaxess Technologies is a Cambridge, MA life sciences company developing a shelf‑stable MIMIX skin patch for vaccines and therapeutics. Its MIMIX™ platform pairs a proprietary microarray patch and applicator with dissolvable microarray tips made from advanced biomaterials to enable high levels of dose delivery control and payload flexibility. The patch does not require refrigeration, facilitating delivery to low‑resource settings. The company intends to use the funding to advance its GLP‑1 program, continue in vivo work with mRNA, and expand and scale manufacturing process capabilities. Vaxess raised $12M in the reported round, and its total equity and non‑dilutive funding now exceeds $90M. Rachel Sha has been appointed CEO as Michael Schrader steps down. Vaxess is developing a shelf-stable, potentially self-applicable vaccine patch using its MIMIX™ sustained release patch technology. The patch is engineered for stability, does not require refrigeration, and can be shipped to and applied in low-resource settings. The company is focusing on translating mRNA lipid nanoparticles stored in silk fibroin matrices into its patch and accelerating mRNA vaccine patch development. In April it reported mRNA stability results showing silk fibroin formulations protect mRNA LNPs through drying and maintain in vivo potency after storage at 37°C for two weeks. Vaxess has raised grant and venture capital funding from groups including RA Capital, The Engine, BARDA, DARPA, NIH, NSF and the Gates Foundation, bringing total equity and non-dilutive funding to more than $80M following the latest raise. The company has a collaboration with AstraZeneca to evaluate an RNA-based pandemic influenza prototype vaccine in patch format and is led by co-founder and CEO Michael Schrader. Vaxess is a Cambridge, MA–based life sciences company developing a shelf-stable vaccine patch designed for potential self-application. Its core product is the MIMIX sustained-release patch technology, which delivers controlled release to simulate the pace of a natural infection and boost immune responses. Engineered for stability, the patch does not require refrigeration and can be shipped to and applied in low-resource settings. In December the company published initial results from a phase 1 trial in 45 healthy adults testing an H1N1 antigen from partner GC Biopharma delivered via the MIMIX Patch, evaluating safety, reactogenicity, tolerability and immunogenicity at two dose levels (7.5 μg and 15 μg) versus placebo. Vaxess is led by CEO Michael Schrader and intends to use newly raised capital to accelerate development efforts. The recent financing and trial data position the company to advance clinical development of its shelf-stable, self-administered vaccine technology. Vaxess Technologies is developing the MIMIX sustained-release patch technology to administer vaccines and therapeutics. The patch provides controlled release that simulates the pace of a natural infection, producing a slower, stronger, and enduring immune response to boost vaccine effectiveness. Engineered for stability, the patch does not require refrigeration and can be shipped to and applied in low-resource settings. Vaxess recently launched a phase 1 trial for an H1 influenza vaccine delivered by VX-103 and intends to use new funding to support that trial. The company is led by CEO Michael Schrader and is based in Cambridge, MA. Vaxess raised $27M in a Series B to advance its clinical development efforts.

Total raised

$75M

Funding rounds

6

Latest round

Equity

Latest activity

Apr 2025